These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18715212)

  • 1. Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes.
    Chandra ST; Priya G; Khurana ML; Jyotsna VP; Sreenivas V; Dwivedi S; Ammini AC
    Diabetes Technol Ther; 2008 Oct; 10(5):363-8. PubMed ID: 18715212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
    Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O
    Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs.
    Zhou J; Zheng F; Guo X; Yang H; Zhang M; Tian H; Guo L; Li Q; Mo Y; Jia W
    Diabetes Metab Res Rev; 2015 Oct; 31(7):725-33. PubMed ID: 25952634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients.
    Güvener N; Gedik O
    Acta Diabetol; 1999 Jun; 36(1-2):93-7. PubMed ID: 10436259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
    Lin S; Chen M; Chen W; Lin K; Mu P; Zhu B; Xu W; Wang M; Weng J; Zeng L
    J Diabetes Res; 2018; 2018():2791584. PubMed ID: 30420969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC; Tsang LW; Sorensen JP; Cockram CS
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
    Charbonnel B; Schernthaner G; Brunetti P; Matthews DR; Urquhart R; Tan MH; Hanefeld M
    Diabetologia; 2005 Jun; 48(6):1093-104. PubMed ID: 15889234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
    Ristic S; Collober-Maugeais C; Pecher E; Cressier F
    Diabet Med; 2006 Jul; 23(7):757-62. PubMed ID: 16842480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes.
    Salman S; Salman F; Satman I; Yilmaz Y; Ozer E; Sengül A; Demirel HO; Karşidağ K; Dinççağ N; Yilmaz MT
    Curr Med Res Opin; 2001; 16(4):296-306. PubMed ID: 11268714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recovery of β-cell functions with low-dose insulin therapy: study in newly diagnosed type 2 diabetes mellitus patients.
    Bhattacharya S; Ammini AC; Jyotsna V; Gupta N; Dwivedi S
    Diabetes Technol Ther; 2011 Apr; 13(4):461-5. PubMed ID: 21355720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of efficacy and tolerability of gliclazide and metformin combination: a multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin.
    Pareek A; Chandurkar N; Zawar S; Agrawal N
    Am J Ther; 2010; 17(6):559-65. PubMed ID: 20093927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the combination of insulin and gliclazide compared with insulin alone in type 2 diabetic patients with secondary failure to oral hypoglycemic agents.
    Aschner P; Kattah W
    Diabetes Res Clin Pract; 1992 Oct; 18(1):23-30. PubMed ID: 1446575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure.
    Chazan AC; Gomes MB
    Braz J Med Biol Res; 2001 Jan; 34(1):49-56. PubMed ID: 11151028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes.
    Perriello G; Pampanelli S; Di Pietro C; Brunetti P;
    Diabet Med; 2006 Mar; 23(3):246-52. PubMed ID: 16492206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus.
    Li Y; Xu L; Shen J; Ran J; Zhang Y; Wang M; Yan L; Cheng H; Fu Z
    Diabetes Res Clin Pract; 2010 Apr; 88(1):42-7. PubMed ID: 20060192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study).
    Barnett AH; Krentz AJ; Strojek K; Sieradzki J; Azizi F; Embong M; Imamoglu S; Perusicová J; Uliciansky V; Winkler G
    Diabetes Obes Metab; 2008 Dec; 10(12):1239-47. PubMed ID: 18494813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment--the Diadem Study.
    Cathelineau G; de Champvallins M; Bouallouche A; Lesobre B
    Metabolism; 1997 Dec; 46(12 Suppl 1):31-4. PubMed ID: 9439556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation.
    Leiter LA; Shestakova MV; Trubitsyna NP; Piletič M; Satman I
    Diabetes Res Clin Pract; 2016 Feb; 112():50-56. PubMed ID: 26653612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.